🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Zeynep Eroglu

Moffitt Cancer Center

ORCID: 0000-0002-2307-7030
MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

(2023)10.1158/1078-0432.c.6530586.v1
Top 100%
0DataRank
Top 100%0 citations

Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, Clayton Wyatt +15 more

Papers

Driven by 22 papers — median percentile 0. Top paper: “Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial”.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y
N/A
4.8DataRank · unranked
171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501
N/A
1.3DataRank · unranked
18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092
N/A
0.705DataRank · unranked
109 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535
N/A
0.520DataRank · unranked
31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9507
N/A
0.434DataRank · unranked
17 citations

Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani +13 more

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9511
N/A
0.239DataRank · unranked
3 citations

Janice M. Mehnert, Anita Giobbie‐Hurder, Kari Kendra, Gino K. In, April K.S. Salama +14 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502
N/A
0DataRank · unranked
21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21542
N/A
0DataRank · unranked
6 citations

Michael J. Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani +7 more

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

Cancer(2023)10.1002/cncr.35029
N/A
0DataRank · unranked
11 citations

Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph Markowitz, Andrew S. Brohl +6 more

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps9603
N/A
0DataRank · unranked
7 citations

James Moon, Yana G. Najjar, Rupesh Kotecha, Vadim Spektor, Michael C. Wu +6 more

Data from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

(2023)10.1158/1078-0432.c.6530586.v1
Top 100%
0DataRank
Top 100%0 citations

Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, Clayton Wyatt +15 more

Supplementary Table 5 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

(2023)10.1158/1078-0432.22480995
Top 100%
0DataRank
Top 100%0 citations

Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, Clayton Wyatt +15 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1
N/A
0DataRank · unranked
0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Data from Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

(2023)10.1158/2326-6066.c.6550279.v1
N/A
0DataRank · unranked
0 citations

Zhihua Chen, Jiannong Li, Eslam Mohamed, Michael A. Davies, Inna Smalley +15 more

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2768
N/A
0DataRank · unranked
11 citations

Zeynep Eroglu, Islam Eljilany, Jonathan S. Zager, R. Gonzalez, Amod A. Sarnaik +13 more

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331
N/A
0DataRank · unranked
125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0652
N/A
0DataRank · unranked
9 citations

Michael J. Shamblott, Andrew S. Brohl, Amod A. Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani +13 more

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Pigment Cell & Melanoma Research(2020)10.1111/pcmr.12861
N/A
0DataRank · unranked
56 citations

Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu +13 more

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1694
N/A
0DataRank · unranked
166 citations

Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, Clayton Wyatt +15 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141
N/A
0DataRank · unranked
102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

Cancer Immunology Research(2021)10.1158/2326-6066.cir-20-0905
N/A
0DataRank · unranked
48 citations

Zhihua Chen, Jiannong Li, Eslam Mohamed, Michael A. Davies, Inna Smalley +15 more

Melanoma brain metastases: Biological basis and novel therapeutic strategies

Experimental Dermatology(2021)10.1111/exd.14286
N/A
0DataRank · unranked
44 citations

Alpaslan Özgün, Zeynep Eroglu, Keiran S.M. Smalley, Manali Phadke